Exploring Recombinant Human Proepiregulin (EREG): Advances and Applications

Recombinant Human Proepiregulin (EREG)

Recombinant Human Proepiregulin (EREG),  processed, refers to a genetically engineered form of proepiregulin, a precursor protein involved in cellular signaling pathways. This partially processed variant is produced by recombinant technology and may retain specific functional domains or structural features relevant to its biological activity, serving as a tool for studying molecular mechanisms or as a potential therapeutic agent.


Cell Signaling Research

EREG can be used as a tool to investigate the signaling pathways involved in cellular proliferation, differentiation, and migration. Its partial processing may allow for the study of specific regulatory mechanisms or interactions with other molecules.

Tissue Regeneration

EREG has been implicated in wound healing and tissue regeneration processes. Recombinant EREG may be explored for its potential to promote tissue repair and regeneration in various medical applications.

Drug Development

EREG and its signaling pathways are potential targets for drug development in various diseases, including cancer, inflammatory disorders, and cardiovascular diseases. Recombinant EREG can be utilized in preclinical studies to assess the efficacy and safety of novel therapeutic agents.


Biological Activity

Despite being partially processed, recombinant EREG retains its biological activity, allowing it to interact with its receptors and initiate cellular signaling pathways accurately.



Production of recombinant EREG through genetic engineering techniques ensures consistency and reproducibility, facilitating its use in research, biopharmaceutical development, and clinical applications.


Recombinant EREG can be produced under stringent quality control measures to ensure purity and safety, minimizing the risk of contamination or adverse effects in experimental or therapeutic settings.

Your Dynamic Snippet will be displayed here... This message is displayed because you did not provided both a filter and a template to use.
Revolutionizing Genetic Editing: The Role of Recombinant AICDA